Key Highlights

  • Total Revenue grew 15% to USD 151.8 million in the third quarter, with testing revenue up 15% to USD 146.4 million.
  • Decipher Prostate revenue rose 12% to USD 92.3 million and Afirma revenue rose 19% to USD 51.5 million, with Volume for each test up 12%.
  • GAAP Net Income was USD 31.5 million, or USD 0.38 per diluted share, and non-GAAP Diluted Earnings per Share were USD 0.51, flat year over year.
  • The board authorized a repurchase of up to USD 100 million of common stock, expiring after 12 months.

Solid Growth, but Decipher Volume Disappoints

Veracyte (NASDAQ:VCYT) reported third-quarter 2026 results on November 4, 2026. The cancer diagnostics company, whose tests include Afirma, Decipher Prostate, Prosigna and Decipher Bladder, delivered total volume of 52,744 tests, up 15%. The chief executive said Afirma outperformed while Decipher Prostate volume was below expectations, at about 29,900 tests. Product revenue rose 40% to USD 4.6 million on Prosigna adoption after trial results, and the company secured Medicare reimbursement for its Prosigna breast test. It also acquired Convergent Genomics, adding a urinary tumor DNA platform. Testing volume was 49,498 tests, up 13%, including about 19,100 Afirma tests. More than 1 million patients have now been served by Veracyte tests. Prosigna IVD adoption followed phase III OPTIMA trial results presented at a major cancer meeting.

Margins Improve but Spending Rises

Total gross Margin was 71%, versus 69%, and non-GAAP gross margin was 74%. GAAP operating expenses rose to USD 90.5 million from USD 68.3 million, while non-GAAP operating expenses grew 24% to USD 72.9 million. Adjusted EBITDA of USD 41.2 million, a non-GAAP measure, was 27.2% of revenue and up 4% year over year. Operating Cash Flow was USD 40.3 million in the quarter, and cash and short-term investments totaled USD 370.5 million at September 30, 2026. GAAP net income rose USD 12.4 million, and diluted earnings per share were USD 0.14 higher than a year earlier. Nine-month operating cash flow was USD 121.3 million, USD 37.6 million above last year.

A Narrower 2026 Outlook Frames the Buyback

The company now expects 2026 total revenue of USD 590 million to USD 593 million, versus prior guidance of USD 590 million to USD 596 million. Testing revenue guidance moved to USD 571 million to USD 573 million from USD 576 million to USD 582 million. Adjusted EBITDA margin guidance above 26% was maintained. The buyback may be executed through open market purchases or other methods at the company's discretion, funded from cash, and does not obligate any purchases. Prostate test adoption and reimbursement remain key risks. The company expects minimal revenue from recently launched tests this year. Biopharmaceutical and other revenue was USD 0.7 million versus USD 0.8 million.

Where Things Stand

A buyback and a trimmed outlook can sit together, but the filing does not say what the board intended. Veracyte (NASDAQ:VCYT) grew revenue 15% and generated strong cash, while narrowing the top end of its guidance and acknowledging Decipher volume below expectations. The repurchase is optional and discretionary. Next markers are Decipher Prostate volume trends, Afirma momentum, the new bladder and breast launches, and the pace of any share repurchases. The release says the company's financial profile lets it keep investing in growth. Total gross margin of 71% and an adjusted EBITDA margin of 27.2% show profitability remained solid.